02297 RAINMED-B
- 0.159
- +0.003+1.92%
RAINMED-B News
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Runmed-B (02297.HK) was increased by 300,000 shares by Chairman and Executive Director Huo Yunfei
Glonghui, May 3, 丨 According to the latest equity disclosure data of the Stock Exchange, on April 29, 2024, Runmed-B (02297.HK) was increased by 300,000 shares by Chairman of the Board of Directors and Executive Director Huo Yunfei at an average price of HK$0.14 per share on the market, involving approximately HK$42,000. After the increase in holdings, Huo Yunfei's latest shareholding was 218,733,000 shares, and the shareholding ratio increased from 18.70% to 18.73%.
Runmaid-B (02297.HK) received 300,000 additional shares worth HK$42,000 from Huo Yunfei
On April 30, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 30, Huo Yunfei increased his share holdings of $Runmed-B (02297.HK) by $300,000 at an average price of HK$0.14 per share on April 29, worth about HK$42,000. After the increase in holdings, Huo Yunfei's latest shareholding was 219 million shares, and the good position ratio increased from 18.70% to 18.73%. Additional Information: Mr. Huo Yunfei was interested in options to receive up to 2,996,400 Share
潤邁德-B：二零二三年年度報告
Rainmed-B (02297) announces 2023 annual results. Shareholders' share loss of 116 million yuan narrowed by 91.4% year-on-year
Rainmed-B (02297) announced its results for the year ended December 31, 2023, and the group achieved acceptance during the period...
RAINMED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Rainmed-B (02297.HK) plans to hold a board meeting on March 28 to consider and approve annual results
Glonghui, March 8 | Runmed-B (02297.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and publication of the Company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any), and to deal with other matters.
RAINMED-B: Date of Board Meeting
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Runmed-B (02297.HK) was granted 47,000 additional shares of common stock by Huo Yunfei, worth approximately HK$19,700
On January 11, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 11, Huo Yunfei increased his share holdings of $Runmed-B (02297.HK) by $47,000 at an average price of HK$0.42 per share on January 11, worth about HK$19,700. After the increase in holdings, Huo Yunfei's latest shareholding was 218 million shares, with a good position ratio of 18.70%. Additional Information: Mr. Huo Yunfei was considering options to receive up to 2,996,400 Shares unde
Runmed-B (02297.HK) was granted 42,000 additional shares of common stock by Huo Yunfei, worth approximately HK$17,200
On January 10, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 10, Huo Yunfei increased his share holdings of $Runmed-B (02297.HK) by $42,000 at an average price of HK$0.41 per share on January 9, worth about HK$17,200. After the increase in holdings, Huo Yunfei's latest shareholding was 218 million shares, and the good position ratio increased from 18.69% to 18.70%. Additional Information: Mr. Huo Yunfei was considering options to receive up to 2,996,400 Shar
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Runmed-B (02297.HK) received 263,000 shares from Chairman of the Board and Executive Director Huo Yunfei
Glonghui, January 2 | According to the Stock Exchange's latest equity disclosure data, on December 28, 2023, Runmed-B (02297.HK) received 263,000 shares from Chairman of the Board of Directors and Executive Director Huo Yunfei on the market at an average price of HK$0.462 per share, involving approximately HK$121,500. After the increase in holdings, Huo Yunfei's latest shareholding was 218,344,000 shares, and the shareholding ratio increased from 18.67% to 18.69%.
Runmed-B (02297.HK) received 263,000 additional shares of common shares by Huo Yunfei, worth approximately HK$121,500
On December 29, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on December 29, Huo Yunfei increased his share holdings of $RunMed-B (02297.HK) by $263,000 at an average price of HK$0.462 per share on December 28, worth about HK$121,500. After the increase in holdings, Huo Yunfei's latest shareholding was 218 million shares, and the good position ratio rose from 18.67% to 18.69%. Additional Information: Mr. Huo Yunfei was considering options to receive up to 2,996,4
Medicine 2023: Winter is still around the corner, spring is getting stronger, innovative drugs “going overseas” welcome a big explosion, health insurance policies continue to warm | year-end inventory
“Science and Technology Innovation Board Daily”, December 27 (Reporter Xu Hong) Although the pharmaceutical industry is still cold in winter in 2023, the signs of “recovery” continue to increase. In particular, as the overall health insurance policy enters the optimization stage, not only will fundamental risks be further released, but it is also expected to greatly increase the certainty of growth of domestically produced innovative drugs.
Financial News Agency Venture Capital Connect: In November, domestic healthcare financing of 5.931 billion yuan increased 49% month-on-month, and innovative drugs led the popularity
① In November 2023, there were 109 financing incidents in the domestic healthcare sector (excluding IPOs, targeted increases, etc.), a year-on-year decrease of 31% and an increase of 76% over the previous year; ② The total amount of financing disclosed in the healthcare sector during the same period was about 5.931 billion yuan, a decrease of 6% over the previous year and an increase of 49% over the previous year.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Analysis
Price Target
No Data
